Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Liver Cancer Drugs Market $4.5 Billion by 2027

The global market for liver cancer drugs expected to be valued at $4.5 billion by 2027, expanding at a double-digit CAGR of 18.0% during the forecast period, driven by unhealthy lifestyles, growing geriatric population, high incidence of HCC, and strong pipeline of novel drugs and combination therapies.

Global Liver Cancer Drugs Market

Hepatocellular cancer (HCC) is the most common type of primary liver cancer, accounting for about 90 percent of cases.  Each year, approximately 40,000 people in the United States are diagnosed with cancer that originates in the liver.

Treatment options include surgery (hepatectomy), liver transplantation, embolization procedures: transarterial embolization (TAE) and transarterial chemoembolization (TACE).

  • Chemotherapies that may be used alone or in combination include cisplatin, doxorubicin, and mitomycin.

Only four oral multi-kinase inhibitors (MKIs) have been approved as targeted therapies for hepatocellular carcinoma.

  • Nexavar, Stivarga, Lenvima and Cabometyx are the approved as chemotherapy drugs for HCC treatment in the US, France, Germany, Italy, Spain, UK, Japan, and China.

Types of radiation therapy used in the treatment of liver cancer include: stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), and 3-dimensional conformal radiation therapy (3D-CRT).


The pipeline for hepatocellular carcinoma is dominated by angiogenesis inhibitors and immune checkpoint inhibitors that are being developed as combination therapies.

  • Targeted therapies for second-line treatment constitute the largest proportion of the HCC pipeline. Phase III pipeline of liver cancer drugs include atezolizumab (Tecentriq), bevacizumab (Avastin), durvalumab (Imfinzi), ramucirumab (Cyramza), tislelizumab, and tremelimumab.
    • Findings from a recent phase lll clinical trial suggested that cabozantinib (Cabometyx, Exelixis) significantly improved outcomes in patients with advanced HCC. Cabozantinib is a vascular endothelial growth factor receptor (VEGFR)-2 inhibitor.

The global hepatocellular carcinoma drugs market research report estimates market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global liver cancer (HCC) drugs market segmented by drug class (product/brand) – angiogenesis inhibitors [Cyramza (Ramucirumab), Avastin (Bevacizumab)], multi-kinase inhibitors [Nexavar (Sorafenib Tosylate), Stivarga (Regorafenib), Lenvima (Lenvatinib), Cabometyx (Cabozantinib)], PDL1 inhibitors [Tecentriq (Atezolizumab), Imfinzi (Durvalumab)], PD1 inhibitors [Opdivo (Nivolumab), Keytruda (Pembrolizumab), BGB-A317 (Tislelizumab)], CTLA4 inhibitors [Yervoy (Ipilimumab), Tremelimumab], and geography.

  • Based on the drug classes, the multi-kinase inhibitors (MKIs) segment accounted for the largest share of the total market, whereas the recently launched immune checkpoint inhibitors (ICIs) or immune-oncology (IO) agents segment expected to witness the fastest growth rate in the near future.
    • Among the multi-kinase inhibitors, in 2007, Bayer Healthcare/Amgen/Onyx’s Nexavar was approved as a first-line treatment for developed markets (US, EU5, Japan).
      • The market is predominantly driven by sales of Nexavar, which is the standard of care for patients with advanced forms of the disease. Nexavar dominates the systemic therapy landscape across all treatment settings.
      • In 2017, Bayer Healthcare’s regorafenib (Stivarga) was approved as a second-line treatment by the FDA.
        • Bayer and Amgen dominate the HCC market with the only approved targeted therapies.
      • In 2018, Eisai Co Ltd.’s Lenvima was approved to use in patients with a common form of liver cancer. The drug was approved as the first therapy in over a decade in the United States to treat previously untreated patients with an advanced or intermediate stage of unresectable HCC. Eisai Co., Ltd. and Merck have entered into global strategic oncology collaboration for lenvima (lenvatinib mesylate).
    • Immunotherapy has recently emerged as a new treatment option for HCC. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years. New drug launches in both the first- and second-line settings is likely to expand the untapped HCC market.
      • For example, in 2017, the FDA granted accelerated approval to Bristol-Myers Squibb’s programmed cell death protein 1 (PD1) inhibitor, nivolumab (Opdivo) for patients with advanced HCC who were previously treated with the targeted therapy sorafenib.
        • Opdivo is the only biologic immunotherapy drug approved as second-line treatment for hepatocellular carcinoma immunotherapy in United States.

The global liver cancer drugs market research report is further divided by geography into North America (U.S.), Europe (U.K., Germany, France, Italy, Spain), and Asia Pacific (Japan, China).

  • In terms of geography, the United States accounted for more than 45% of the market. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region.

Moreover, the global liver cancer (HCC) market report provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also includes major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global liver cancer treatment market and profiled in this report include AstraZeneca plc, Bayer AG, BeiGene, Ltd., Bristol-Myers Squibb and Company, Eisai Co. Ltd., Eli Lilly and Company, Exelixis, Inx., Ipsen Pharma Biotech SAS, Merck & Co., Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., and Roche Holdings AG (Genentech/Chugai Pharmaceutical Co., Ltd.).

  • Drug Class (Product/Brand)
    • Angiogenesis Inhibitors
      • Cyramza (Ramucirumab)
      • Avastin (Bevacizumab)
    • Multi-Kinase Inhibitors (MKIs)
      • Nexavar (Sorafenib Tosylate)
      • Stivarga (Regorafenib)
      • Lenvima (Lenvatinib)
      • Cabometyx (Cabozantinib)
    • Programmed Cell Death Protein 1 Ligand 1 (PDL1) Inhibitors
      • Tecentriq (Atezolizumab)
      • Imfinzi (Durvalumab)
    • Programmed Cell Death Protein 1 (PD1) Inhibitors
      • Opdivo (Nivolumab)
      • Keytruda (Pembrolizumab)
      • Tislelizumab
    • Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Inhibitors
      • Yervoy (Ipilimumab)
      • Tremelimumab
  • Geography
    • North America (U.S.)
    • Europe (U.K., Germany, France, Italy, Spain)
    • Asia Pacific (Japan, China)
  • Company Profiles
    • AstraZeneca plc
    • Bayer AG
    • BeiGene, Ltd.
    • Bristol-Myers Squibb and
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Exelixis, Inc.
    • Ipsen Pharma Biotech SAS
    • Merck & Co., Inc.
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Roche Holdings AG (Genentech/Chugai Pharmaceutical Co., Ltd.)

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]